In a report released today, Steven Wheen from Jarden maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of A$314.37.

Investing.com-- Australian biopharmaceutical giant CSL Ltd (ASX: CSL) reported a rise in half-year net profit, driven ...

Let's see how this biotech giant performed during the first half of FY 2025. The post CSL share price on watch amid $2.1b ...

Csl Ltd ( ($CSLLY) ) has released its Q2 earnings. Here is a breakdown of the information Csl Ltd presented to its investors.

CSL Ltd (ASX: CSL) shares dropped to a 52-week low on Tuesday. Do brokers believe that this is a buying opportunity? Let's ...

In a report released yesterday, David Stanton from Jefferies maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of ...

“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in ...

CEO Paul McKenzie announced a reaffirmation of guidance for fiscal 2025, targeting NPATA growth of 10% to 13%. He highlighted strong results from CSL Behring and growth in CSL Vifor, while ...

CSL's Seqirus vaccine unit saw revenue decline 9% YoY to $1.66 billion for the six months ended December 31, 2024, falling 15% short of analyst expectations. This weakness in the vaccine segment ...

Biotech firm CSL Behring has announced the four-year results from the pivotal HOPE-B study confirming the long-term ...

CSL delivered a messy result. Although they did say they are on track to achieve FY guidance, gross margins and 1H adjusted ...